A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

June 23, 2021

Study Completion Date

June 23, 2021

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

APL-2

Complement (C3) Inhibitor

Trial Locations (30)

1112

St. Lukes Medical Centre, Quezon City

1229

Makati Medical Centre, Makati City

1604

The Medical City, Pasig

2600

Baguio General Hospital, Benguet

4217

Mary Mediatrix Medical Center, Lipa City

6000

Perpetual Succour Hospital, Cebu City

10400

Ramathibodi Hospital, Bangkok

10700

Siriraj Hospital, Bangkok

12120

Thammasat University Hospital, Pathum Thani

15003

Hospital Nacional Dos de Mayo, Lima

15072

Hospital Cayetano Heredia, Jesús María

15102

Hospital Cayetano Heredia, San Martín de Porres

40002

Srinagaring Hospital, Khon Kaen

50200

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

59100

University Malaya Medical Centre, Kuala Lumpur

68000

Hospital Ampang, Ampang

90110

Songklanagaring Hospital, Songkhla

169608

Singapore General Hospital (SGH), Singapore

Unknown

Research Center of the Colombian Clinical Life Cancer Foundation, Medellín

Julian Coronel Medical Center, Santiago de Cali

Queen Mary Hospital, Hong Kong

Princess Margaret Hospital, Kwai Chung

Prince and Wales Hospital, Shatin

Hospital Universitario Dr.Jose Eleuterio Gonzalez, Monterrey

Clinical Centre of Serbia, Belgrade

Hospital for Tropical disease, Bangkok

Phramongkutklao Hospital, Bangkok

20-081

Independent Public Clinical Hospital, Lubin

02-776

Institute of Hematology and Transfusiology, Warsaw

50-220

EMC Medical Institute, Wroclaw

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY